GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » Total Liabilities

RGTLF (Argent Biopharma) Total Liabilities : $8.83 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Argent Biopharma Total Liabilities?

Argent Biopharma's Total Liabilities for the quarter that ended in Dec. 2024 was $8.83 Mil.

Argent Biopharma's quarterly Total Liabilities declined from Dec. 2023 ($11.15 Mil) to Jun. 2024 ($11.03 Mil) and declined from Jun. 2024 ($11.03 Mil) to Dec. 2024 ($8.83 Mil).

Argent Biopharma's annual Total Liabilities increased from Jun. 2022 ($9.60 Mil) to Jun. 2023 ($12.09 Mil) but then declined from Jun. 2023 ($12.09 Mil) to Jun. 2024 ($11.03 Mil).


Argent Biopharma Total Liabilities Historical Data

The historical data trend for Argent Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Total Liabilities Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.82 14.76 9.60 12.09 11.03

Argent Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.23 12.09 11.15 11.03 8.83

Argent Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Argent Biopharma's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.085+(0.545+0.012
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+2.389+0+0)
=11.03

Total Liabilities=Total Assets (A: Jun. 2024 )-Total Equity (A: Jun. 2024 )
=7.163--3.868
=11.03

Argent Biopharma's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.353+(0.465+0.0099999999999996
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.83

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=1.937--6.892
=8.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argent Biopharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.